Last reviewed · How we verify
ticagrelor + ASA
Ticagrelor and aspirin work together to inhibit platelet aggregation through different pathways, reducing blood clot formation.
Ticagrelor and aspirin work together to inhibit platelet aggregation through different pathways, reducing blood clot formation. Used for Acute coronary syndrome (ACS) for reduction of cardiovascular death, myocardial infarction, and stent thrombosis, Secondary prevention of atherothrombotic events in patients with prior myocardial infarction.
At a glance
| Generic name | ticagrelor + ASA |
|---|---|
| Sponsor | Peking University Third Hospital |
| Drug class | Dual antiplatelet agent |
| Target | P2Y12 receptor (ticagrelor); cyclooxygenase (aspirin) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Ticagrelor is a P2Y12 receptor antagonist that reversibly blocks ADP-induced platelet activation, while aspirin irreversibly inhibits cyclooxygenase (COX) to prevent thromboxane A2 synthesis. Together, this dual antiplatelet combination provides more potent inhibition of platelet function than either agent alone, reducing thrombotic events in acute coronary syndromes and other cardiovascular conditions.
Approved indications
- Acute coronary syndrome (ACS) for reduction of cardiovascular death, myocardial infarction, and stent thrombosis
- Secondary prevention of atherothrombotic events in patients with prior myocardial infarction
Common side effects
- Bleeding
- Dyspnea
- Bradycardia
- Nausea
- Ventricular pauses
Key clinical trials
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- The 10-Year Extended Follow-up of the DACAB Trial
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome (PHASE4)
- Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (PHASE3)
- Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone (PHASE3)
- Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (PHASE4)
- Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ticagrelor + ASA CI brief — competitive landscape report
- ticagrelor + ASA updates RSS · CI watch RSS
- Peking University Third Hospital portfolio CI